Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Wisconsin, Madison
With
National Cancer Institute (NCI)
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Prostate Cancer
Castrate Resistant Disease with rising PSA despite continuous treatment with orchiectomy or a LHRH agonist
Rising PSA after treatment and withdrawal of anti-androgen
Serum Testosterone \<50ng/mL
Normal organ function per laboratory tests
You may not be if
No evidence of immunosuppression or on treatment with immunosuppressive agents
Cannot have discontinued LHRH agonist treatment (if not previously treated by orchiectomy) within 6 months prior to study entry
Must not be concurrently taking other medications or supplements with known hormonal effects (other than the LHRH agonist noted above).
Cannot have any evidence for metastatic disease on bone or CT scan
Unable or unwilling to undergo two leukapheresis procedure
Clareo Health | Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
